Amorepacific Corporation (KRX:090430)

Theseus Pharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	599,464	451,543	506,379	449,598	537,694	793,728
Short-Term Investments	40,134	46,662	61,774	74,669	101,826	57,882
Trading Asset Securities	287,949	256,504	511,821	391,486	490,839	166,463
Cash & Short-Term Investments	927,548	754,709	1,079,974	915,753	1,130,358	1,018,074
Cash Growth	-22.09%	-30.12%	17.93%	-18.99%	11.03%	15.47%
Accounts Receivable	378,950	386,487	292,901	286,269	297,046	285,018
Other Receivables	13,220	17,626	20,310	22,367	32,176	12,475
Receivables	412,027	424,517	329,203	339,030	330,857	298,552
Inventory	482,284	497,801	394,312	408,934	493,224	414,483
Prepaid Expenses	-	29,701	28,525	27,240	32,422	39,091
Other Current Assets	68,954	28,080	120,182	24,113	27,600	55,533
Total Current Assets	1,890,813	1,734,809	1,952,196	1,715,070	2,014,461	1,825,732
Property, Plant & Equipment	2,403,583	2,433,764	2,542,688	2,603,769	2,687,828	2,793,781
Long-Term Investments	47,542	47,831	326,260	283,933	367,698	74,031
Goodwill	791,071	791,145	104,152	106,877	9,605	8,763
Other Intangible Assets	969,373	982,799	236,528	250,874	192,075	200,011
Long-Term Accounts Receivable	-	-	616	1,644	2,313	3,164
Long-Term Deferred Tax Assets	52,240	50,942	13,846	57,854	84,608	82,890
Other Long-Term Assets	698,092	716,341	681,594	766,604	714,309	694,678
Total Assets	6,877,582	6,783,508	5,886,511	5,801,783	6,116,714	5,701,918
Accounts Payable	84,837	95,965	86,442	80,676	123,410	117,618
Accrued Expenses	123,868	191,146	182,047	156,109	181,653	175,867
Short-Term Debt	281,752	306,195	244,109	223,414	199,124	154,160
Current Portion of Leases	56,470	61,264	55,347	69,006	94,761	132,867
Current Income Taxes Payable	67,575	55,009	22,688	41,109	89,963	6,097
Other Current Liabilities	543,827	386,126	222,624	260,803	468,574	379,338
Total Current Liabilities	1,158,328	1,095,705	813,257	831,117	1,157,485	965,947
Long-Term Leases	65,620	72,759	50,948	64,785	96,221	133,748
Long-Term Deferred Tax Liabilities	229,940	235,817	106,368	91,266	79,488	90,076
Other Long-Term Liabilities	45,964	46,963	38,739	30,962	35,160	43,918
Total Liabilities	1,505,856	1,457,500	1,013,806	1,022,508	1,372,414	1,237,520
Common Stock	34,525	34,525	34,525	34,525	34,525	34,508
Additional Paid-In Capital	619,602	623,231	793,879	791,599	795,834	723,509
Retained Earnings	4,634,738	4,600,956	4,101,401	4,010,087	3,937,775	3,847,747
Treasury Stock	-9,194	-9,731	-3,713	-8,632	-18,814	-101,389
Comprehensive Income & Other	6,165	3,390	-28,104	-28,966	11,689	-36,521
Total Common Equity	5,285,836	5,252,371	4,897,988	4,798,613	4,761,008	4,467,854
Minority Interest	85,890	73,637	-25,283	-19,338	-16,709	-3,456
Shareholders' Equity	5,371,726	5,326,008	4,872,705	4,779,275	4,744,300	4,464,398
Total Liabilities & Equity	6,877,582	6,783,508	5,886,511	5,801,783	6,116,714	5,701,918
Total Debt	403,841	440,218	350,403	357,205	390,106	420,776
Net Cash (Debt)	523,706	314,491	729,571	558,548	740,252	597,298
Net Cash Growth	-35.09%	-56.89%	30.62%	-24.55%	23.93%	88.52%
Net Cash Per Share	7592.51	4559.78	10570.28	8095.68	10771.85	8719.55
Filing Date Shares Outstanding	68.98	68.98	58.47	58.44	58.4	57.95
Total Common Shares Outstanding	68.98	68.98	69.02	69	68.95	68.5
Working Capital	732,485	639,104	1,138,939	883,953	856,975	859,786
Book Value Per Share	76629.51	76148.63	70961.50	69549.85	69049.35	65223.18
Tangible Book Value	3,525,392	3,478,427	4,557,308	4,440,862	4,559,328	4,259,080
Tangible Book Value Per Share	51108.10	50430.08	66025.76	64364.70	66124.37	62175.43
Land	815,194	815,194	849,339	816,978	816,099	831,524
Buildings	1,061,160	1,531,716	1,567,369	1,568,304	1,555,102	1,487,216
Machinery	389,814	1,451,505	1,427,335	1,482,596	1,582,520	1,520,647
Construction In Progress	10,280	6,505	42,581	30,645	24,835	14,661

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.